FPHAX Performance — Select Pharmaceuticals Portfolio
Data updated: 2026-07-24
FPHAX returned +9.13% year to date and +44.55% over one year to May 2026. Annualised returns are +18.50% over 3 years and +13.21% over 5 years. The fund beat its Global Health Care Equity category average: $100 invested three years ago grew to $166, against $126 for the category, and to $145 over one year, against $120. Volatility over the past three years was 17.83% a year. In the 12 months to May 2026 the fund took in a net $12.1M, and assets reached $1.50B.
FPHAX Growth of $100
What $100 invested in Select Pharmaceuticals Portfolio grew to, compounded from monthly returns reported on SEC Form N-PORT, against the Global Health Care Equity category average over the same months.
| Period | FPHAX | Category average |
|---|---|---|
| 1 year (Jun 2025 – May 2026) | $145 | $120 |
| 3 years (Jun 2023 – May 2026) | $166 | $126 |
| 5 years (Jun 2021 – May 2026) | $186 | $103 |
| Since data start (Sep 2019 – May 2026) | $259 | $154 |
FPHAX Trailing Returns
Total returns to May 2026, from SEC N-PORT.
| Period | Total return |
|---|---|
| YTD | +9.13% |
| 1 year | +44.55% |
| 3 years (annualised) | +18.50% |
| 5 years (annualised) | +13.21% |
FPHAX Annual Returns
Calendar-year total returns of Select Pharmaceuticals Portfolio, compounded from monthly SEC N-PORT returns. Partial years show the months covered.
| Year | Total return |
|---|---|
| 2026 (Jan–May) | +9.13% |
| 2025 | +30.30% |
| 2024 | +9.44% |
| 2023 | +12.51% |
| 2022 | +0.99% |
| 2021 | +11.82% |
| 2020 | +11.07% |
| 2019 (Sep–Dec) | +17.78% |
FPHAX Monthly Returns
Monthly total returns as reported on SEC Form N-PORT.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | +2.2% | +5.4% | −6.8% | +0.5% | +8.2% | — | — | — | — | — | — | — |
| 2025 | +3.7% | +6.0% | −9.1% | +2.0% | −3.5% | +2.3% | −3.1% | +6.6% | +6.0% | +9.1% | +9.9% | −1.4% |
| 2024 | +5.2% | +8.5% | +3.9% | −2.1% | +5.5% | +3.4% | −0.4% | +7.0% | −6.2% | −5.1% | −2.2% | −6.9% |
| 2023 | 0.0% | −4.5% | +4.3% | +5.3% | +0.2% | +2.0% | −0.4% | +3.1% | −4.5% | −4.1% | +4.5% | +6.7% |
| 2022 | −5.4% | +0.4% | +5.1% | −2.7% | −0.9% | +1.2% | +2.3% | −5.9% | −2.5% | +6.4% | +5.5% | −1.8% |
| 2021 | +1.4% | −0.3% | −0.3% | +2.3% | +3.2% | +3.9% | +0.5% | +2.4% | −5.1% | +4.3% | −6.2% | +6.1% |
| 2020 | −0.6% | −6.3% | −3.4% | +12.0% | +3.0% | +0.7% | +1.6% | +1.9% | −0.7% | −6.2% | +7.9% | +2.0% |
| 2019 | — | — | — | — | — | — | — | — | +0.4% | +5.4% | +3.9% | +7.1% |
FPHAX Risk
Risk measures from monthly returns over Jun 2023 – May 2026.
- 3-year volatility (annualised): 17.83%
- 3-year Sharpe ratio: 0.79 (vs 4.5% risk-free rate)
- Best month: +9.88% (Nov 2025)
- Worst month: −9.08% (Mar 2025)
FPHAX Fund Flows
Monthly money in and out of Select Pharmaceuticals Portfolio, from SEC Form N-PORT.
- 12-month net flow: $12.1M
- 12-month gross sales (incl. reinvestments): $424.1M
- Sales ÷ redemptions: 1.03×
| Month | Sales | Redemptions | Net flow |
|---|---|---|---|
| May 2026 | $28.5M | $33.8M | −$5.2M |
| Apr 2026 | $53.6M | $37.1M | $16.6M |
| Mar 2026 | $23.9M | $32.9M | −$9.1M |
| Feb 2026 | $36.3M | $27.9M | $8.4M |
| Jan 2026 | $86.2M | $38.1M | $48.2M |
| Dec 2025 | $92.4M | $25.5M | $66.9M |
| Nov 2025 | $39.4M | $21.4M | $18.0M |
| Oct 2025 | $19.1M | $38.3M | −$19.2M |
| Sep 2025 | $12.3M | $34.3M | −$22.1M |
| Aug 2025 | $11.7M | $44.5M | −$32.8M |
| Jul 2025 | $9.7M | $46.2M | −$36.5M |
| Jun 2025 | $10.9M | $32.0M | −$21.1M |
FPHAX Assets Under Management
Net assets of Select Pharmaceuticals Portfolio by report date, from SEC N-PORT filings.
| Report date | Net assets |
|---|---|
| 2026-05-31 | $1.50B |
| 2026-02-28 | $1.52B |
| 2025-11-30 | $1.34B |
| 2025-08-31 | $1.08B |
| 2025-05-31 | $1.11B |
| 2025-02-28 | $1.32B |
| 2024-11-30 | $1.42B |
| 2024-08-31 | $1.91B |
| 2024-05-31 | $1.48B |
| 2024-02-29 | $1.08B |
| 2023-11-30 | $819.53M |
| 2023-08-31 | $856.87M |
For information only. Not investment advice: figures are as reported in SEC filings and may contain errors or be out of date. Past performance does not guarantee future results.